Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Lawrence Dougan, M.D.,Ph.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K08DK114563 (DOUGAN, MICHAEL LAWRENCE) Sep 1, 2017 - Aug 31, 2022
    NIH
    Regulation of brown fat metabolism by the immune receptor PD-L1
    Role: Principal Investigator
  2. F32CA210568 (DOUGAN, MICHAEL LAWRENCE) Jul 1, 2016 - Jun 30, 2017
    NIH
    Targeting cytokines to the tumor microenivronment using a high affinity single domain antibody to PD-L1
    Role: Principal Investigator
  3. R01CA177684 (GARCIA, KENAN CHRISTOPHER) May 1, 2014 - Apr 30, 2026
    NIH
    Engineering of macrophage phagocytosis for cancer and stem cell immunotherapy
    Role: Co-Principal Investigator
  4. F30AG030298 (DOUGAN, MICHAEL LAWRENCE) Oct 1, 2007 - Sep 30, 2011
    NIH
    The Contribution of Chronic Inflammation to Pulmonary Adenocarcinoma
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med. 2021 Jul 14. PMID: 34260849.
    Citations: 2     Fields:    
  2. Dougan M. Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. Gastroenterology. 2021 Jul 10. PMID: 34256056.
    Citations:    Fields:    
  3. Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, Rothenberg M, Khozin S, Guidon AC, Dougan M, Zubiri L, Petrillo L, Sise ME, Villani AC, Johnson DB, Rahma O, Sharon E. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021 Jul; 9(7). PMID: 34215691.
    Citations:    Fields:    
  4. Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL, Cohen JV, Dietrich J, Dougan M, Doughty CT, Dubey D, Gelfand JM, Guptill JT, Johnson DB, Juel VC, Kadish R, Kolb N, LeBoeuf NR, Linnoila J, Mammen AL, Martinez-Lage M, Mooradian MJ, Naidoo J, Neilan TG, Reardon DA, Rubin KM, Santomasso BD, Sullivan RJ, Wang N, Woodman K, Zubiri L, Louv WC, Reynolds KL. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7). PMID: 34281989.
    Citations: 1     Fields:    Translation:Humans
  5. Pisuchpen N, Durbin SM, Mooradian MJ, Fintelmann FJ, Reynolds KL, Dougan M, Kambadakone A. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol. 2021 Jun 03. PMID: 34081152.
    Citations:    Fields:    
  6. Lenehan PJ, Cirella A, Uchida AM, Crowley SJ, Sharova T, Boland G, Dougan M, Dougan SK, Heckler M. Type 2 immunity is maintained during cancer-associated adipose tissue wasting. Immunother Adv. 2021 Jan; 1(1):ltab011. PMID: 34291232.
    Citations:    
  7. Roehle K, Qiang L, Ventre KS, Heid D, Ali LR, Lenehan P, Heckler M, Crowley SJ, Stump CT, Ro G, Godicelj A, Bhuiyan AM, Yang A, Quiles Del Rey M, Biary T, Luoma AM, Bruck PT, Tegethoff JF, Nopper SL, Li J, Byrne KT, Pelletier M, Wucherpfennig KW, Stanger BZ, Akin JJ, Mancias JD, Agudo J, Dougan M, Dougan SK. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021 05 19; 13(594). PMID: 34011631.
    Citations:    Fields:    Translation:HumansAnimalsCells
  8. Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, McCreary J, Boschert T, Wang ES, Suo S, Marangoni F, Mempel TR, Long HW, Wucherpfennig KW, Dougan M, Gray NS, Yuan GC, Goel S, Tolaney SM, Dougan SK. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021 May 03. PMID: 33941591.
    Citations: 1     Fields:    
  9. Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522. PMID: 33655682.
    Citations:    Fields:    Translation:Humans
  10. Walsh MJ, Dougan M. Checkpoint blockade toxicities: Insights into autoimmunity and treatment. Semin Immunol. 2021 Mar 14; 101473. PMID: 33726931.
    Citations: 2     Fields:    
  11. Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021 03 18; 184(6):1575-1588. PMID: 33675691.
    Citations: 2     Fields:    
  12. Uchida AM, Dougan M. Editorial: Penetration of food protein through the oesophageal mucosa-is this where EoE starts? Aliment Pharmacol Ther. 2021 02; 53(3):447-448. PMID: 33428254.
    Citations:    Fields:    Translation:HumansAnimals
  13. Sun H, Jain A, Leone MJ, Alabsi HS, Brenner LN, Ye E, Ge W, Shao YP, Boutros CL, Wang R, Tesh RA, Magdamo C, Collens SI, Ganglberger W, Bassett IV, Meigs JB, Kalpathy-Cramer J, Li MD, Chu JT, Dougan ML, Stratton LW, Rosand J, Fischl B, Das S, Mukerji SS, Robbins GK, Westover MB. CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease 2019 Prognosis. J Infect Dis. 2021 01 04; 223(1):38-46. PMID: 33098643.
    Citations: 10     Fields:    Translation:Humans
  14. Sacks CA, Dougan M, McCoy TH, Zheng A, Buonomo G, North CM, Metlay JP, Walensky RP. The Association Between Symptoms and COVID-19 Test Results Among Healthcare Workers. Ann Surg. 2020 12; 272(6):e329-e332. PMID: 32941277.
    Citations:    Fields:    Translation:Humans
  15. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM, Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZ. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020 10 30; 11(1):5493. PMID: 33127906.
    Citations: 84     Fields:    Translation:HumansCellsPHPublic Health
  16. Thompson LL, Katznelson E, Leet DE, Durbin SM, Yoon J, Reynolds KL, Dougan ML, Chen ST. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 01; 142:143-146. PMID: 33268234.
    Citations:    Fields:    Translation:Humans
  17. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 12 10; 383(24):2333-2344. PMID: 33085857.
    Citations: 272     Fields:    Translation:Humans
  18. Fernandes RA, Su L, Nishiga Y, Ren J, Bhuiyan AM, Cheng N, Kuo CJ, Picton LK, Ohtsuki S, Majzner RG, Rietberg SP, Mackall CL, Yin Q, Ali LR, Yang X, Savvides CS, Sage J, Dougan M, Garcia KC. Immune receptor inhibition through enforced phosphatase recruitment. Nature. 2020 10; 586(7831):779-784. PMID: 33087934.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  19. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021 03; 160(4):1384-1393. PMID: 33080231.
    Citations: 7     Fields:    Translation:Humans
  20. Dougan M. Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunol Res. 2020 10; 8(10):1230-1235. PMID: 33004412.
    Citations:    Fields:    
  21. Durbin SM, Mooradian MJ, Fintelmann FJ, Zubiri L, Chute DF, Kambadakone A, Pisuchpen N, Reynolds KL, Dougan M. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2). PMID: 33033184.
    Citations:    Fields:    
  22. Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 02; 34(2):426-437. PMID: 32884128.
    Citations: 6     Fields:    
  23. Shannon VR, Anderson R, Blidner A, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson DB, Suarez-Almazor ME, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer. 2020 Dec; 28(12):6145-6157. PMID: 32880733.
    Citations:    Fields:    Translation:Humans
  24. Badran YR, Leet DE, Dougan M. Immune-related adverse events: what we've learned and where we're heading. Expert Rev Anticancer Ther. 2020 09; 20(9):727-730. PMID: 32726153.
    Citations:    Fields:    Translation:HumansAnimals
  25. Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Anderson R. Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer. 2020 Dec; 28(12):6111-6117. PMID: 32857220.
    Citations: 1     Fields:    Translation:Humans
  26. Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6129-6143. PMID: 32856210.
    Citations: 1     Fields:    Translation:Humans
  27. Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6119-6128. PMID: 32856211.
    Citations:    Fields:    Translation:Humans
  28. Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I, Cooksley T, Anderson R, Blidner A, Choi J, Dougan M, Ginex P, Girotra M, Shannon VR, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6159-6173. PMID: 32856212.
    Citations:    Fields:    Translation:Humans
  29. Cooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, Choi J, Dougan M, Glezerman I, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Support Care Cancer. 2020 Dec; 28(12):6175-6181. PMID: 32856213.
    Citations:    Fields:    Translation:Humans
  30. North CM, Dougan ML, Sacks CA. Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond. N Engl J Med. 2020 Oct 08; 383(15):1406-1408. PMID: 32668133.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  31. Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, Boland GM, Nowak JA, Dougan SK, Dougan M, Yuan GC, Wucherpfennig KW. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22. PMID: 32603654.
    Citations: 21     Fields:    Translation:HumansCells
  32. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. PMID: 32567084.
    Citations: 4     Fields:    Translation:HumansCells
  33. Sun H, Jain A, Leone MJ, Alabsi HS, Brenner LN, Ye E, Ge W, Shao YP, Boutros CL, Wang R, Tesh RA, Magdamo C, Collens SI, Ganglberger W, Bassett IV, Meigs JB, Kalpathy-Cramer J, Li MD, Chu JT, Dougan M, Stratton L, Rosand J, Fischl B, Das S, Mukerji SS, Robbins GK, Westover MB. COVID-19 Outpatient Screening: a Prediction Score for Adverse Events. medRxiv. 2020 Jun 22. PMID: 32607523.
    Citations: 1     
  34. Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer. 2020 06; 8(1). PMID: 32581063.
    Citations: 3     Fields:    Translation:HumansCells
  35. Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, Johnson DB, Sullivan RJ, Dougan M. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020 05; 8(1). PMID: 32414860.
    Citations: 5     Fields:    Translation:Humans
  36. Abu-Sbeih H, Faleck DM, Dougan M, Wang Y. Reply to Y. Inagaki et al. J Clin Oncol. 2020 05 20; 38(15):1749-1750. PMID: 32250720.
    Citations:    Fields:    Translation:Humans
  37. Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep. 2020 Mar 17; 22(4):15. PMID: 32185493.
    Citations: 4     Fields:    Translation:Humans
  38. Crowley SJ, Bruck PT, Bhuiyan MA, Mitchell-Gears A, Walsh MJ, Zhangxu K, Ali LR, Jeong HJ, Ingram JR, Knipe DM, Ploegh HL, Dougan M, Dougan SK. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biol. 2020 02; 10(2):190235. PMID: 32019478.
    Citations: 1     Fields:    Translation:AnimalsCells
  39. Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, Ploegh HL. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunol Res. 2020 04; 8(4):518-529. PMID: 32019780.
    Citations: 12     Fields:    Translation:AnimalsCells
  40. Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest. 2020 01 02; 130(1):51-61. PMID: 31895048.
    Citations: 15     Fields:    Translation:Humans
  41. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583. PMID: 31800340.
    Citations: 27     Fields:    Translation:Humans
  42. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069.
    Citations:    
  43. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404. PMID: 32162817.
    Citations: 1     Fields:    Translation:Humans
  44. Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2020 Jan; 76(2):233-243. PMID: 31361907.
    Citations: 12     Fields:    Translation:Humans
  45. Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer. 2019 11 07; 7(1):292. PMID: 31699151.
    Citations: 16     Fields:    Translation:Humans
  46. Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020 01; 25(1):6-14. PMID: 31694890.
    Citations: 5     Fields:    Translation:Humans
  47. Dougan SK, Dougan M. SMAC mimetics throw a molecular switch to control TH17 responses. Sci Signal. 2019 08 27; 12(596). PMID: 31455724.
    Citations: 1     Fields:    Translation:Cells
  48. Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFa blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019 08 22; 7(1):226. PMID: 31439050.
    Citations: 23     Fields:    Translation:Humans
  49. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746. PMID: 31349048.
    Citations: 2     Fields:    Translation:Humans
  50. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999. PMID: 31286682.
    Citations: 15     Fields:    Translation:Humans
  51. Dougan M, Dougan SK. Programmable bacteria as cancer therapy. Nat Med. 2019 07; 25(7):1030-1031. PMID: 31270505.
    Citations: 3     Fields:    Translation:HumansCells
  52. Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019 06; 40(6):511-523. PMID: 31053497.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  53. Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity. 2019 04 16; 50(4):796-811. PMID: 30995500.
    Citations: 37     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  54. Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO, Ploegh H. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019 04 16; 116(16):7624-7631. PMID: 30936321.
    Citations: 57     Fields:    Translation:Animals
  55. Bello E, Cohen JV, Mino-Kenudson M, Dougan M. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer. 2019 02 11; 7(1):41. PMID: 30744698.
    Citations: 5     Fields:    Translation:Humans
  56. Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019 01; 565(7738):186-191. PMID: 30626941.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  57. Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist. 2018 09; 23(9):991-997. PMID: 29853659.
    Citations: 25     Fields:    Translation:Humans
  58. Dougan SK, Dougan M. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy. 2018 07; 10(9):787-796. PMID: 29807457.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  59. Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, Weinberg RA. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 2018 04 11; 10(436). PMID: 29643230.
    Citations: 84     Fields:    Translation:AnimalsCells
  60. Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, Fedorov AA, Bonanno JB, Le Gall C, Crowley S, Espinosa C, Biary T, Keliher EJ, Weissleder R, Almo SC, Dougan SK, Ploegh HL, Dougan M. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A. 2018 04 10; 115(15):3912-3917. PMID: 29581255.
    Citations: 48     Fields:    Translation:HumansAnimalsCells
  61. Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunol Res. 2018 04; 6(4):389-401. PMID: 29459478.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  62. Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan M, Dougan SK. IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunol Res. 2018 01; 6(1):25-35. PMID: 29187357.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  63. Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol. 2017; 8:1547. PMID: 29230210.
    Citations: 39     Fields:    
  64. Ingram JR, Dougan M, Rashidian M, Knoll M, Keliher EJ, Garrett S, Garforth S, Blomberg OS, Espinosa C, Bhan A, Almo SC, Weissleder R, Lodish H, Dougan SK, Ploegh HL. PD-L1 is an activation-independent marker of brown adipocytes. Nat Commun. 2017 09 21; 8(1):647. PMID: 28935898.
    Citations: 32     Fields:    Translation:AnimalsCells
  65. Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, Dougan M. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10184-10189. PMID: 28874561.
    Citations: 36     Fields:    Translation:Animals
  66. Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, Grotenbreg GM, Bhan A, Weinberg RA, Ploegh HL. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017 Aug 07; 214(8):2243-2255. PMID: 28666979.
    Citations: 70     Fields:    Translation:AnimalsCells
  67. Dougan M, Dougan SK. Targeting Immunotherapy to the Tumor Microenvironment. J Cell Biochem. 2017 10; 118(10):3049-3054. PMID: 28332219.
    Citations: 16     Fields:    Translation:HumansAnimals
  68. Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK. Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. . 2017 03; 16(3):428-439. PMID: 28148714.
    Citations: 6     Translation:HumansAnimalsCells
  69. Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016 May 10; 113(19):E2646-54. PMID: 27091975.
    Citations: 84     Fields:    Translation:AnimalsPHPublic Health
  70. Tafesse FG, Rashidfarrokhi A, Schmidt FI, Freinkman E, Dougan S, Dougan M, Esteban A, Maruyama T, Strijbis K, Ploegh HL. Disruption of Sphingolipid Biosynthesis Blocks Phagocytosis of Candida albicans. PLoS Pathog. 2015 Oct; 11(10):e1005188. PMID: 26431038.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  71. Rashidian M, Keliher E, Dougan M, Juras PK, Cavallari M, Wojtkiewicz GR, Jacobsen J, Edens JG, Tas JM, Victora G, Weissleder R, Ploegh H. The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. ACS Cent Sci. 2015 Jun 24; 1(3):142-147. PMID: 26955657.
    Citations: 38     
  72. Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol Res. 2013 Aug; 1(2):99-111. PMID: 24459675.
    Citations: 24     Fields:    Translation:AnimalsCells
  73. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest. 2011 Jun; 121(6):2436-46. PMID: 21537082.
    Citations: 41     Fields:    Translation:AnimalsCells
  74. Yarchoan M, Dougan ML, Tjota MY, Milliner BH, Adler BL, Armah KA, Gooley TA, Close KL, Close J, Hirsch IB. Who will manage American patients with diabetes? Residents' career preferences and perceptions of diabetes care. Endocr Pract. 2011 Mar-Apr; 17(2):235-9. PMID: 21041164.
    Citations: 2     Fields:    Translation:Humans
  75. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010 Sep 27; 207(10):2195-206. PMID: 20837698.
    Citations: 52     Fields:    Translation:HumansAnimalsCells
  76. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol. 2009 Apr; Chapter 20:Unit 20.11. PMID: 19347848.
    Citations: 10     Fields:    Translation:HumansAnimals
  77. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009; 27:83-117. PMID: 19007331.
    Citations: 224     Fields:    Translation:HumansAnimalsCells
  78. Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med. 2008 Feb 18; 205(2):267-70. PMID: 18268042.
    Citations: 17     Fields:    Translation:HumansAnimals
  79. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007 Jul; 117(7):1902-13. PMID: 17557120.
    Citations: 81     Fields:    Translation:AnimalsCells
  80. Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 2007 Aug 01; 110(3):954-61. PMID: 17483299.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  81. Dougan ML, Chin JL, Solt K, Hansen DE. Rapid cleavage of cyclic tertiary amides of Kemp's triacid: effects of ring structure. Bioorg Med Chem Lett. 2004 Aug 16; 14(16):4153-6. PMID: 15261260.
    Citations: 1     Fields:    Translation:Cells
  82. Zaitseva M, King LR, Manischewitz J, Dougan M, Stevan L, Golding H, Golding B. Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus. Infect Immun. 2001 Jun; 69(6):3817-26. PMID: 11349047.
    Citations: 5     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Dougan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (297)
Explore
_
Co-Authors (145)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.